Literature DB >> 33569111

The Association Between BMP-2, UQCC1 and CX3CR1 Polymorphisms and the Risk of Developmental Dysplasia of the Hip.

Evren Gumus1,2, Ebru Temiz3, Baran Sarikaya4, Ozgur Yuksekdag3, Serkan Sipahioglu4, Ataman Gonel3.   

Abstract

OBJECTIVE: Developmental dysplasia of the hip (DDH) is a complicated skeletal disease ranging from subluxation to complete dislocation of the hip as a result of insufficient development of the acetabulum and femur. To date, numerous genes such as C-X3-C motif chemokine receptor 1 (CX3CR1), ubiquinol-cytochrome c reductase complex assembly factor 1 (UQCC1) and growth/differentiation factor 5 (GDF5), have been investigated to elucidate the underlying genetic etiology. Turkish population is one of the communities where DDH patients frequently observed, but almost no study has been conducted to elucidate the genetic etiology. In our study, we aimed to investigate the polymorphism of CX3CR1 rs3732378 and UQCC1 rs6060373, which have been shown to be associated with DDH in different populations. In addition, we aimed to investigate the BMP-2 rs235768 polymorphism which has not been investigated in the etiology of DDH.
METHODS: Overall, 168 subjects (68 participants in the patient group, 100 participants in the control group) were investigated. The participants with following evidence and symptoms were excluded from the two groups: any systemic syndrome, another congenital anomaly, hereditary diseases, breech presentation, history of oligohydramnios, swaddling and high birth weight (> 4000 g). 3 single-nucleotide polymorphisms (SNP) were examined by qRT-PCR method.
RESULTS: For CX3CR1 rs3732378 polymorphism, significant differences were observed in genotypes and allele frequencies (p < 0.0001). This condition was associated with a 12-fold increased risk in recessive modeling and 75-fold increased risk in dominant modeling. There was no significant relationship between DDH and the other two polymorphisms.
CONCLUSIONS: Our work is the first study to investigate DDH and genetic polymorphisms in Turkish population where DDH is observed quite frequently. It is also the first study to investigate the relationship between BMP-2 rs235768 polymorphism and DDH. Our study revealed a clear relationship between CX3CR1 rs3732378 polymorphism and DDH in Turkish population. © Indian Orthopaedics Association 2020.

Entities:  

Keywords:  BMP-2; CX3CR1; Developmental dysplasia of the hip; Single-nucleotide polymorphism; UQCC1

Year:  2020        PMID: 33569111      PMCID: PMC7851229          DOI: 10.1007/s43465-020-00235-y

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.251


  34 in total

1.  Role of Bone Morphogenetic Protein 2 Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin.

Authors:  Ricardo Usategui-Martín; Gemma Vega; Laura Abad-Manteca; Marta Ruiz-Mambrilla; Ismael Calero-Paniagua; Antonio Dueñas-Laita; José L Pérez-Castrillón
Journal:  Basic Clin Pharmacol Toxicol       Date:  2018-08-02       Impact factor: 4.080

Review 2.  The control of chondrogenesis.

Authors:  Mary B Goldring; Kaneyuki Tsuchimochi; Kosei Ijiri
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

3.  CX3CR1 polymorphisms associated with an increased risk of developmental dysplasia of the hip in human.

Authors:  Lianyong Li; Xi Wang; Qun Zhao; Enbo Wang; Lili Wang; Jinshan Cheng; Lijun Zhang; Binbin Wang
Journal:  J Orthop Res       Date:  2016-06-14       Impact factor: 3.494

4.  Relative Risk and Incidence for Developmental Dysplasia of the Hip.

Authors:  Virginie Pollet; Vanessa Percy; Heather J Prior
Journal:  J Pediatr       Date:  2016-11-18       Impact factor: 4.406

Review 5.  Developmental dysplasia of the hip.

Authors:  Carol Dezateux; Karen Rosendahl
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

6.  Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosteal cells enhances osteoblast differentiation and bone formation.

Authors:  Mayurach Samee; Shohei Kasugai; Hisatomo Kondo; Keiichi Ohya; Hitoyata Shimokawa; Shinji Kuroda
Journal:  J Pharmacol Sci       Date:  2008-09-06       Impact factor: 3.337

7.  Genome-wide association study of developmental dysplasia of the hip identifies an association with GDF5.

Authors:  Konstantinos Hatzikotoulas; Andreas Roposch; Karan M Shah; Matthew J Clark; Selina Bratherton; Vasanti Limbani; Julia Steinberg; Eleni Zengini; Kaltuun Warsame; Madhushika Ratnayake; Maria Tselepi; Jeremy Schwartzentruber; John Loughlin; Deborah M Eastwood; Eleftheria Zeggini; J Mark Wilkinson
Journal:  Commun Biol       Date:  2018-05-31

Review 8.  Developmental Dysplasia of Hip: Perspectives in Genetic Screening.

Authors:  Radoslav Zamborsky; Milan Kokavec; Stefan Harsanyi; Doaa Attia; Lubos Danisovic
Journal:  Med Sci (Basel)       Date:  2019-04-11

9.  Long bone structure and strength depend on BMP2 from osteoblasts and osteocytes, but not vascular endothelial cells.

Authors:  Sarah H McBride; Jennifer A McKenzie; Bronwyn S Bedrick; Paige Kuhlmann; Jill D Pasteris; Vicki Rosen; Matthew J Silva
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

Review 10.  Developmental Dysplasia of the Hip: A Review of Etiopathogenesis, Risk Factors, and Genetic Aspects.

Authors:  Stefan Harsanyi; Radoslav Zamborsky; Lubica Krajciova; Milan Kokavec; Lubos Danisovic
Journal:  Medicina (Kaunas)       Date:  2020-03-31       Impact factor: 2.430

View more
  2 in total

1.  Identification of KANSL1 as a novel pathogenic gene for developmental dysplasia of the hip.

Authors:  Xiaowen Xu; Xinying Bi; Jing Wang; Ronghua Gui; Tengyan Li; Lianyong Li; Binbin Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-21       Impact factor: 5.606

2.  Genetic Study of IL6, GDF5 and PAPPA2 in Association with Developmental Dysplasia of the Hip.

Authors:  Stefan Harsanyi; Radoslav Zamborsky; Lubica Krajciova; Milan Kokavec; Lubos Danisovic
Journal:  Genes (Basel)       Date:  2021-06-28       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.